From L-R: Rondo CEO Shelley Force Aldred and CSO Nathan Trinklein

A dy­nam­ic on­col­o­gy duo team up on an I/O start­up fo­cused on next-gen sol­id tu­mor fight­ers

In the no­to­ri­ous­ly flighty biotech in­dus­try, long­time part­ner­ships aren’t nec­es­sar­i­ly the norm. But a pair of on­col­o­gy vets with a his­to­ry of col­lab­o­ra­tion ap­par­ent­ly likes work­ing to­geth­er just fine — and now they’re kick­start­ing an up­start firm on the hunt against sol­id tu­mors.

Ron­do Ther­a­peu­tics launched Wednes­day with a $67 mil­lion Se­ries A and back­ing from J&J, among oth­ers, to build out its plat­form of next-gen T cell en­gagers and bis­pe­cif­ic an­ti­bod­ies tar­get­ing sol­id tu­mors, the new biotech said in a re­lease.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.